For the long-run threat to innovation, considering that companies used public money to develop the vaccine, and it worked in record time, the only thing that should be questioned is the current patent-based system. Innovation seemed to work fine with what amounts to a public process.
David Dayen
David Dayen is the author of Chain of Title: How Three Ordinary Americans Uncovered Wall Street’s Great Foreclosure Fraud, winner of the Studs and Ida Terkel Prize. Follow him on Twitter: @ddayen.
ALL POSTS BY David Dayen
December 10, 2020That should be part of a relief bill entirely focused on getting the vaccine to people as fast as possible. This is The COVID-19 Daily Report for December 10, 2020.
December 9, 2020The Republicans are running out the clock. They have offered up increasingly untenable proposals in a bid to pin the responsibility for no deal on the Democrats.
December 8, 2020Supply chain issues may be a concern; lack of access to the developing world is far greater of a calamity.
December 7, 2020Sens. Warner, Manchin, and Shaheen are conceding to McConnell’s expansive language, sources indicate.
December 4, 2020Radical shifts in the economy cannot be easily managed.
December 2, 2020Plus, another bipartisan gang pitching a probably fruitless deal.
December 1, 2020There’s a gap in transparency and a gap in funding. Plus, looking at the holiday travel stats.
November 25, 2020Out of the tragedy comes a few distinct advances.
November 20, 2020Joe Biden has his chance at a populist, pro-worker statement during his transition.
